News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
264,265 Results
Type
Article (13711)
Company Profile (101)
Press Release (250453)
Section
Business (88013)
Career Advice (465)
Deals (15340)
Drug Delivery (66)
Drug Development (36581)
Employer Resources (49)
FDA (6283)
Job Trends (6193)
News (150157)
Policy (14022)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Pharm Country Standard (1)
Academia (438)
Adcomms (6)
Allergies (28)
Alliances (23202)
ALS (32)
Alzheimer's disease (377)
Antibody-drug conjugate (ADC) (33)
Approvals (6307)
Artificial intelligence (93)
Autoimmune disease (4)
Automation (3)
Bankruptcy (146)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (49)
Biotechnology (40)
Bladder cancer (17)
Brain cancer (13)
Breast cancer (70)
Cancer (521)
Cardiovascular disease (54)
Career advice (406)
Career pathing (10)
CAR-T (17)
Cell therapy (74)
Cervical cancer (4)
Clinical research (30765)
Collaboration (286)
Compensation (116)
Complete response letters (16)
COVID-19 (754)
CRISPR (18)
C-suite (99)
Cystic fibrosis (35)
Data (524)
Denatured (15)
Depression (9)
Diabetes (70)
Diagnostics (1310)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (50)
Drug pricing (61)
Drug shortages (11)
Duchenne muscular dystrophy (26)
Earnings (31876)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37245)
Executive appointments (323)
FDA (6618)
Featured Employer (21)
Friedreich's ataxia (2)
Funding (179)
Gene editing (34)
Generative AI (8)
Gene therapy (90)
GLP-1 (324)
Government (1281)
Grass and pollen (2)
Guidances (14)
Healthcare (3555)
Huntington's disease (4)
IgA nephropathy (8)
Immunology and inflammation (24)
Indications (10)
Infectious disease (783)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (12)
Intellectual property (35)
Interviews (59)
IPO (5869)
IRA (28)
Job creations (2050)
Job search strategy (372)
Kidney cancer (6)
Labor market (7)
Layoffs (175)
Leadership (3)
Legal (3427)
Liver cancer (18)
Lung cancer (71)
Lymphoma (45)
Machine learning (1)
Management (16)
Manufacturing (127)
MASH (28)
Medical device (1272)
Medtech (1274)
Mergers & acquisitions (9620)
Metabolic disorders (222)
Multiple sclerosis (16)
NASH (14)
Neurodegenerative disease (19)
Neuropsychiatric disorders (5)
Neuroscience (528)
NextGen: Class of 2025 (1585)
Non-profit (593)
Northern California (620)
Now hiring (7)
Obesity (126)
Opinion (116)
Ovarian cancer (18)
Pain (44)
Pancreatic cancer (13)
Parkinson's disease (38)
Partnered (5)
Patents (91)
Patient recruitment (26)
Peanut (9)
People (28775)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8007)
Phase II (13013)
Phase III (11679)
Pipeline (307)
Podcasts (44)
Policy (54)
Postmarket research (1401)
Preclinical (3191)
Press Release (25)
Prostate cancer (40)
Psychedelics (8)
Radiopharmaceuticals (118)
Rare diseases (147)
Real estate (2632)
Recruiting (17)
Regulatory (10022)
Reports (13)
Research institute (563)
Resumes & cover letters (55)
RSV (6)
Schizophrenia (31)
Series A (32)
Series B (11)
Service/supplier (3)
Sickle cell disease (30)
Southern California (621)
Special edition (5)
Sponsored (6)
Startups (1626)
State (2)
Stomach cancer (3)
Supply chain (27)
The Weekly (28)
United States (6217)
Vaccines (136)
Venture capitalists (13)
Webinars (10)
Weight loss (89)
Women's health (8)
Worklife (3)
Date
Today (59)
Last 7 days (279)
Last 30 days (1093)
Last 365 days (12354)
2025 (2111)
2024 (12500)
2023 (14247)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15474)
2014 (12423)
2013 (10593)
2012 (11401)
2011 (11923)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (46)
Arkansas (3)
Asia (20015)
Australia (2595)
California (1489)
Canada (813)
China (195)
Colorado (61)
Connecticut (62)
Delaware (49)
Europe (39217)
Florida (267)
Georgia (34)
Idaho (9)
Illinois (166)
India (11)
Indiana (120)
Iowa (1)
Japan (76)
Kansas (54)
Kentucky (12)
Maine (2)
Maryland (227)
Massachusetts (1274)
Michigan (27)
Minnesota (82)
Missouri (21)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (639)
New Mexico (7)
New York (423)
North Carolina (353)
North Dakota (2)
Northern California (620)
Ohio (43)
Oklahoma (4)
Oregon (16)
Pennsylvania (374)
Puerto Rico (5)
Rhode Island (5)
South America (500)
South Carolina (2)
Southern California (621)
Tennessee (29)
Texas (196)
Utah (32)
Virginia (65)
Washington D.C. (29)
Washington State (101)
Wisconsin (12)
264,265 Results for "bioray pharmaceutical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioRay’s ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
February 10, 2025
·
2 min read
FDA
Clinical Trial Application (IND) for BioRay Pharmaceutical’s BR105 Injection Receives U.S. FDA Approval
BioRay Pharmaceutical Co., Ltd. announced on October 7th that its clinical trial application for BR105 Injection has received approval from the United States Food and Drug Administration.
October 24, 2023
·
2 min read
Drug Development
BioRay Announces First-Patient-In for Phase I Clinical Study of BRY812, a Novel LIV-1 Targeting Antibody Drug Conjugate
BioRay Pharmaceutical Co., Ltd. announced that the first patient has been dosed in the Phase I Clinical trial of BRY812, a third-generation antibody-drug conjugate targeting LIV-1 for the treatment of advanced malignant tumors.
November 7, 2023
·
2 min read
Policy
Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China
Recently, BioRay Pharmaceutical Co., Ltd. announced that its independently developed Class I innovative therapeutic biological product, Zuberitamab Injection, indicated for the treatment of CD20-positive diffuse large B-cell lymphoma, was officially approved for marketing by the National Medical Products Administration.
September 13, 2023
·
2 min read
BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1
BioRay Pharmaceutical Co., Ltd. announced that the Investigational New Drug application for the clinical trial of its proprietary BRY812, a novel antibody-drug conjugate targeting human LIV-1 for the treatment of advanced malignant tumors, has been accepted by the China National Medical Products Administration .
May 24, 2023
·
2 min read
Biotech Beach
Bioray Inc. Releases New Products for Teens at Expo West 2023 in Anaheim
Bioray Inc., The Natural Detox Company, is launching RAYZ ® for teens at Natural Products Expo West 2023 at the Anaheim Convention Center March 9th through March 11th , 2023.
March 3, 2023
·
1 min read
Nascent Biotech Receives $750k Milestone Payment from BioRay Pharmaceutical
Nascent Biotech, Inc. is pleased to announce that the Company has received a payment totaling USD $750,000 from BioRay Pharmaceutical, Ltd.
February 23, 2022
·
3 min read
Business
Nascent Biotech and BioRay Pharmaceutical Announce $5,000,000 Exclusive License Agreement for Development and Commercialization of Nascent’s Pritumumab
Nascent Biotech, Inc. (OTCQB:NBIO) and BioRay Pharmaceutical Ltd., today announced that Nascent Biotech has entered into a license agreement with BioRay Pharmaceutical Co Ltd
May 19, 2021
·
4 min read
BioMidwest
Nascent Biotech Regains Worldwide Rights for Pritumumab
Nascent Biotech, Inc. announced that the Company and China based BioRay Pharmaceutical Co have mutually agreed to terminate the license agreement entered into on March 31, 2021.
May 26, 2023
·
2 min read
Biotech Beach
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
ChromaDex Corp., the global authority on nicotinamide adenine dinucleotide research and its application to healthy aging, unveils Niagen+, the first-of-its-kind pharmaceutical-grade Niagen®.
June 13, 2024
·
9 min read
1 of 26,427
Next
